To be honest, this isn't big news and was expected. It shouldn't theoretically have much effect on the share price. It's certainly another tick on the way to where we're going though.
I would note that historically most positive company announcements have had little or no positive impact on the share price (the Retts Ph 3 is the one exception to date).
I'm thinking the only news going forward that might affect the share price in any significant way will be final FDA approval. Those that are very familiar with Neuren know this is 95% and in a discount model this is close to a done deal. But perhaps the wider market that is less familiar looks at this in more binary terms - i.e. the huge future revenue stream Neuren is projected to receive will be ignored until FDA approval is achieved.
NEU Price at posting:
$4.32 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)